Physician profile
Jonathan Rosenzweig, JR.
NPI 1932184140
$388.18
in general payments reported to CMS, 2019-2025
12 companies · $18.10 in 2025
The $18.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $31.33 · 2021: $63.33 · 2022: $51.95 · 2024: $32.35 · 2025: $18.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $94.06 | 2020-2022 | |
| Astellas Pharma US INC | $72.54 | 2019-2024 | Veozah |
| Amgen INC. | $58.16 | 2019-2025 | Evenity |
| Sanofi-Aventis U.S. LLC | $37.24 | 2019 | |
| Novo Nordisk INC | $24.35 | 2019 | |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Gemtesa |
| Abbvie INC. | $15.25 | 2019 | |
| Amarin Pharma, INC. | $15.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.82 | 2022 | |
| Bausch Health US, LLC | $14.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rosenzweig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.